10/26/2020  9:10:00 PM Chg. -0.45 Volume Bid11:35:18 PM Ask10/26/2020 Market Capitalization Dividend Y. P/E Ratio
106.50USD -0.42% 455,449
Turnover: 38.83 mill.
105.60Bid Size: 1,000 125.00Ask Size: 100 5.4 bill.USD 0.00% 99.53

Business description

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for their customers.
 

Management board & Supervisory board

CEO
Christopher Simon
Management board
William P. Burke, Anila Lingamneni, Chad Nikel, David J. Wilson, Dr. Ian Purdy, Jacqueline Scanlan, Josep Lluis Llorens, Kevin O’Kelly-Lynch, Michelle L. Basil, Stewart W. Strong
Supervisory board
Richard Meelia, Cathy Burzik, Charles Dockendorff, Chris Simon, Claire Pomeroy, Dr. Mark Kroll, Ellen M. Zane, Michael J. Coyle, Robert E. Abernathy, Ronald Gelbman
 

Company data

Name: Haemonetics Corporation
Address: 125 Summer Street,Boston, MA 02110, USA
Phone: +1-781-848-7100
Fax: -
E-mail: -
Internet: www.haemonetics.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 3/31
Free Float: 66.00%
IPO date: -

Investor relations

Name: Olga Guyette
IR phone: +1-781-356-9402
IR Fax: -
IR e-mail: investor@haemonetics.com

Company calendar

CW 45 | 11/4/2020 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
66.00%
BlackRock, Inc.
 
11.76%
Wellington Management Group LLC
 
11.28%
The Vanguard Group, Inc.
 
10.96%